文献速递鼻科

Draf 3 额窦手术后慢性鼻窦炎伴鼻息肉患者的 dupilumab 使用率与症状严重程度

Rate of dupilumab use and symptom severity of patients with chronic rhinosinusitis with nasal polyposis after Draf 3 frontal sinusotomy.
PubMed 文献 · Int Forum Allergy Rhinol · 2024-08-07

回顾性分析 2012 至 2022 年单中心 87 例接受 Draf 3 手术的难治性慢性鼻窦炎伴鼻息肉(CRSwNP)患者,评估术后 SNOT-22 改善及需 dupilumab 补救治疗的情况。伴与不伴阿司匹林加重呼吸道疾病(AERD)者术后 24 个月内 SNOT-22 均显著改善,14.9% 最终需 dupilumab 补救;AERD 患者 24.1% 需补救。

要点

  • Draf 3 术后 24 个月内 CRSwNP 患者 SNOT-22 评分显著改善,伴与不伴 AERD 者均获益。
  • 87 例中 14.9% 最终需 dupilumab 补救治疗;21 例 AERD 中 24.1% 需补救。
  • 需 dupilumab 补救与更多次既往鼻窦手术、既往阿司匹林脱敏及更差术前 Lund-MacKay 评分相关。

核心结论

  • Draf 3 手术治疗 CRSwNP 与术后 24 个月 SNOT-22 评分显著改善相关,仅 14.9% 患者需 dupilumab 补救治疗。
  • 伴 AERD 患者更可能需要 dupilumab 补救,但研究期间 75.1% 的 AERD 患者未接受该生物制剂治疗。

研究设计与样本

  • 回顾性综述,纳入 2012 至 2022 年一家三级中心接受 Draf 3 手术的 87 例 CRSwNP 患者。
  • 比较术后需与不需 dupilumab 补救治疗患者的临床人口学变量,分析至补救治疗时间,并用鼻腔鼻窦结局测试(SNOT-22)纵向评估疾病特异性结局。

主要发现

  • 87 例 CRSwNP 患者中 24.1% 伴 AERD。
  • 伴 AERD 者(p < 0.001)与不伴 AERD 者(p = 0.01)术后 24 个月内 SNOT-22 评分均显著改善。
  • 14.9% 患者最终需 dupilumab 补救治疗;21 例 AERD 患者中 24.1% 最终需 dupilumab 补救治疗。
  • dupilumab 补救与更多既往鼻窦手术次数(p = 0.02)、既往阿司匹林脱敏(p = 0.02)及更差术前 Lund-MacKay 评分(p < 0.001)相关。
  • 生物制剂补救与额隐窝前后径无关(p = 0.20)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The indications for endoscopic modified Lothrop procedure (Draf 3) in patients with refractory chronic rhinosinusitis with nasal polyposis (CRSwNP) remain unclear. This study evaluates the effectiveness of Draf 3 for refractory CRSwNP focusing on improvements in disease severity and need for subsequent dupilumab rescue therapy. METHODS: Retrospective review of patients with CRSwNP undergoing Draf 3 surgery at a tertiary center between 2012 and 2022. Clinicodemographic variables were compared across those who did versus did not require rescue with postoperative dupilumab. Time to postoperative dupilumab rescue was analyzed and longitudinal disease-specific outcomes were measured using the sinonasal outcomes test (SNOT-22). RESULTS: Within 87 patients with CRSwNP, 24.1% had aspirin-exacerbated respiratory disease (AERD). Significant improvement in SNOT-22 score was found in CRSwNP with AERD (p < 0.001) and without AERD (p = 0.01) up to 24 months postoperative. 14.9% eventually required rescue with a dupilumab. More specifically, of 21 patients with AERD, 24.1% eventually required rescue with dupilumab. Dupilumab rescue was associated with a greater number of prior sinus surgeries (p = 0.02), prior aspirin desensitization (p = 0.02), and worse preoperative Lund-MacKay scores (p < 0.001). No association between biologic rescue and frontal recess antero-posterior diameter was found (p = 0.20). CONCLUSIONS: Draf 3 surgery in CRSwNP was associated with significant improvement in SNOT-22 score at 24 months. Furthermore, only 14.9% of patients required dupilumab rescue. Patients with AERD were more likely to require rescue with dupilumab even though 75.1% avoided treatment with the biologic over the study period.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Ji K, Kellerman H, Mace JC, et al. Rate of dupilumab use and symptom severity of patients with chronic rhinosinusitis with nasal polyposis after Draf 3 frontal sinusotomy. Int Forum Allergy Rhinol. 2024. PMID: 39110114. doi:10.1002/alr.23424

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。